Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%.

Bristol-Myers Squibb Co (NYSE:BMY) said its treatment showed promising results in a Phase IIb study that compared its investigational compound–known as BMS-663068–with Reyataz boosted with ritonavir. Bristol-Myers Squibb Co (NYSE:BMY) rose 0.34 percent to $56.61 yesterday on volume of 8.94million shares. The intra-day range of the Bristol-Myers Squibb Co (NYSE:BMY) stock was $55.52 to $57.06. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $93.42billion.

Abbott Laboratories (NYSE:ABT) was upgraded by equities researchers at Thomson Reuters/Verus from a “hold” rating to a “buy” rating in a research report issued on Monday. Abbott Laboratories (NYSE:ABT)’s stock on Mar 05, 2014 reported a decrease of -0.82% to the closing price of $39.79. Its fifty two weeks range is $32.70 -$40.49. The total market capitalization recorded $61.40billion. The overall volume in the last trading session was 8.29million shares. In its share capital, Abbott Laboratories (NYSE:ABT) has 1.55billion outstanding shares.

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Eli Lilly and Company’s ( LLY ) Evista (60 mg). On Wednesday, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) advanced 0.79% to close the day at $49.80. Company return on investment (ROI) is 4.90% and its monthly performance is recorded as 13.98%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly revenue growth is 23.48%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone